What it means
CVRs turn up most often when a bidder and a target cannot agree on how much an uncertain asset is worth. Rather than argue, the bidder pays a lower cash price and hands each target shareholder a CVR that pays out if the asset delivers.
The classic setting is pharmaceuticals, where a drug in development might be worth nothing or billions depending on trial results. A buyer will not pay full price for that lottery ticket, and the seller will not accept a discount, so a CVR splits the difference by tying part of the price to the outcome.
CVRs come in two broad flavours. Tradeable CVRs are listed and can be bought and sold like a security, while non-tradeable CVRs simply sit with the original shareholder until the milestone date passes.
Tradeable versions give holders an exit but also expose them to price swings driven by rumour rather than data. Valuing a CVR means estimating the probability of the milestone, multiplying by the payout, and discounting that expected amount back to today.
The maths is straightforward; the judgement about probability is where nearly all the disagreement lives. The main practical risk is definitional.
Milestones written loosely, such as "approval in a major market", can produce years of litigation, whereas milestones tied to a dated, specific regulatory decision usually settle cleanly. Holders should also watch who controls the milestone.
If the acquirer decides how hard to push a regulatory filing, the CVR terms normally include an obligation to use reasonable efforts, because otherwise the paying party could simply let the deadline slide.
In practice
Real-world examples.
Example
A large drugmaker acquires a small biotech for $12.00 per share in cash plus a non-tradeable CVR worth $4.00 if a cancer therapy receives approval by a set date. Shareholders who wanted certainty took the cash element and simply waited on the rest.
Example
A mining group agrees a takeover that includes a CVR paying out if a disputed exploration licence is granted within three years. The licence is refused, the CVR expires worthless, and the acquirer avoids overpaying for a permit that never existed.
Example
An insurance acquirer issues tradeable CVRs linked to how a legacy claims reserve actually settles. The CVRs trade at $0.35 for two years, then jump to $1.10 when the reserve is released at a lower cost than feared. Shareholders who sold early at $0.35 captured certainty but gave up most of the eventual value.
Formula
Calculation
Value of a CVR = (Probability of milestone x Payout per CVR) / (1 + discount rate) ^ years to resolution.
A specialty pharmaceuticals bidder offers $18.00 in cash per share plus one CVR paying $3.00 if a lead therapy is approved within twelve months. Analysts assess the probability of approval at 55%, so the expected payout is 0.55 x $3.00 = $1.65. Discounting one year at 10% gives $1.65 / 1.10 = $1.50 per CVR. Across the 20,000,000 CVRs issued, the total value of the arrangement is 20,000,000 x $1.50 = $30,000,000, which is the amount the bidder has effectively deferred rather than paid on day one.Case study
Seen in the real world.
Consider an illustrative situation involving Halden Therapeutics, a fictional mid-cap pharmaceutical company bidding for a smaller rival with one promising respiratory compound. The target's board insisted the compound alone was worth $6.00 per share; Halden's analysts thought the honest number was closer to $1.50 once the odds of approval were factored in.
The deal completed at $18.00 cash plus one CVR per share paying $3.00 on regulatory approval within twelve months. Halden's finance team recognised the CVR liability at $1.50 per unit, or $30,000,000 in total, based on a 55% probability of approval and a 10% discount rate.
Approval came through in month ten and Halden paid the full $3.00 per CVR, a further $60,000,000. Because the payment only happened in the scenario where the compound was genuinely valuable, the board treated it as a good outcome rather than a cost overrun, which is the whole point of the structure in this fictional example.
Watch out
Common mistakes.
- Reading the headline CVR payout as though it were guaranteed cash, when it is a conditional promise that may well expire at zero.
- Ignoring the discount rate and the time to resolution, which can cut the present value of a distant milestone almost in half.
- Assuming every CVR can be sold, when many are non-tradeable and simply sit dormant until the milestone date.
Questions
People also ask.
Are CVRs taxed like ordinary shares?
Tax treatment varies by jurisdiction and by whether the CVR is tradeable, so holders should take specific advice rather than assume capital treatment.
What happens if the milestone is nearly met but not quite?
Nothing is paid, because CVR terms are binary, which is precisely why the wording of the milestone matters so much.
Do CVRs appear on the acquirer's balance sheet?
Yes, an acquirer normally recognises the CVR as a liability at fair value and remeasures it as the probability of the milestone changes.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%Related